First clinical trial of tRNA therapy will start soonnews2026-03-31T11:00:50+00:00March 31st, 2026|Endpoints News|
Enveda’s first clinical readout shows strong eczema resultsnews2026-03-31T11:00:25+00:00March 31st, 2026|Endpoints News|
#ACC26: Merck touts comparator data for oral cholesterol drugnews2026-03-30T18:33:20+00:00March 30th, 2026|Endpoints News|
#AAD26 roundup: Takeda, Alumis, Priovant and Incyte take the stagenews2026-03-30T18:22:30+00:00March 30th, 2026|Endpoints News|
Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?news2026-03-30T15:28:50+00:00March 30th, 2026|Endpoints News|
#ACC26: Kardigan’s repeat dosing of blood pressure drug has no benefit over single shotnews2026-03-30T14:22:03+00:00March 30th, 2026|Endpoints News|
#ACC26: Braveheart Bio’s Hengrui-originated pill posts China data in heart muscle diseasenews2026-03-30T13:30:46+00:00March 30th, 2026|Endpoints News|
#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcomanews2026-03-30T11:33:22+00:00March 30th, 2026|Endpoints News|
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failurenews2026-03-29T16:00:49+00:00March 29th, 2026|Endpoints News|
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibodynews2026-03-28T21:24:57+00:00March 28th, 2026|Endpoints News|
